206 related articles for article (PubMed ID: 26164583)
1. How omalizumab came to be studied as a therapy for chronic spontaneous/idiopathic urticaria.
Kaplan AP; Joseph K; Saini SS
J Allergy Clin Immunol Pract; 2015; 3(4):648. PubMed ID: 26164583
[No Abstract] [Full Text] [Related]
2. Total IgE and atopic status in patients with severe chronic spontaneous urticaria unresponsive to omalizumab treatment.
Asero R; Ferrucci S; Casazza G; Marzano AV; Cugno M
Allergy; 2019 Aug; 74(8):1561-1563. PubMed ID: 30801715
[No Abstract] [Full Text] [Related]
3. The use of anti-IgE therapy beyond allergic asthma.
Stokes JR; Casale TB
J Allergy Clin Immunol Pract; 2015; 3(2):162-6. PubMed ID: 25609342
[TBL] [Abstract][Full Text] [Related]
4. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.
Navinés-Ferrer A; Serrano-Candelas E; Molina-Molina GJ; Martín M
J Immunol Res; 2016; 2016():8163803. PubMed ID: 28097159
[TBL] [Abstract][Full Text] [Related]
5. New insights into the utility of omalizumab.
Cardet JC; Casale TB
J Allergy Clin Immunol; 2019 Mar; 143(3):923-926.e1. PubMed ID: 30690050
[TBL] [Abstract][Full Text] [Related]
6. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria.
Gericke J; Metz M; Ohanyan T; Weller K; Altrichter S; Skov PS; Falkencrone S; Brand J; Kromminga A; Hawro T; Church MK; Maurer M
J Allergy Clin Immunol; 2017 Mar; 139(3):1059-1061.e1. PubMed ID: 27838346
[No Abstract] [Full Text] [Related]
7. The discovery and development of omalizumab for the treatment of asthma.
Licari A; Marseglia G; Castagnoli R; Marseglia A; Ciprandi G
Expert Opin Drug Discov; 2015; 10(9):1033-42. PubMed ID: 25979110
[TBL] [Abstract][Full Text] [Related]
8. Use of omalizumab in uncontrolled chronic spontaneous urticaria also improved latex-induced contact urticaria.
Di Leo E; Calogiuri G; Macchia L; Nettis E
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):300-302. PubMed ID: 29802908
[No Abstract] [Full Text] [Related]
9. Treatment of idiopathic anaphylaxis with omalizumab.
Sanchez-Valenzuela MC; Garcia-Saucedo JC; Motoa G; Carrillo-Martin I; Gonzalez-Estrada A
Ann Allergy Asthma Immunol; 2019 Dec; 123(6):612-613. PubMed ID: 31568858
[No Abstract] [Full Text] [Related]
10. Successful treatment of four types of chronic urticaria with anti-IgE omalizumab in the same patient.
Nettis E; Di Leo E; Calogiuri G; Foti C; Macchia L
Ann Allergy Asthma Immunol; 2019 Mar; 122(3):336-337. PubMed ID: 30529714
[No Abstract] [Full Text] [Related]
11. Treatment with omalizumab or cyclosporine for resistant chronic spontaneous urticaria.
Koski R; Kennedy KK
Ann Allergy Asthma Immunol; 2017 Nov; 119(5):397-401. PubMed ID: 29150066
[No Abstract] [Full Text] [Related]
12. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
Kaplan AP; Giménez-Arnau AM; Saini SS
Allergy; 2017 Apr; 72(4):519-533. PubMed ID: 27861988
[TBL] [Abstract][Full Text] [Related]
13. Omalizumab, an additional therapy for allergic bronchopulmonary aspergillosis.
Evans MO; Morris MJ; Coop CA; Evans SE
Ann Allergy Asthma Immunol; 2015 Sep; 115(3):250-1. PubMed ID: 26162570
[No Abstract] [Full Text] [Related]
14. Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab.
Weller K; Ohanyan T; Hawro T; Ellrich A; Sussman G; Koplowitz J; Gimenez-Arnau AM; Peveling-Oberhag A; Staubach P; Metz M; Maurer M
Allergy; 2018 Dec; 73(12):2406-2408. PubMed ID: 30076605
[No Abstract] [Full Text] [Related]
15. [Dermatological implications of omalizumab, an anti-IgE antibody].
Di Lucca-Chrisment J
Rev Med Suisse; 2015 Apr; 11(468):779-80, 782-3. PubMed ID: 26021140
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria.
Harris JM; Cabanski CR; Scheerens H; Samineni D; Bradley MS; Cochran C; Staubach P; Metz M; Sussman G; Maurer M
J Allergy Clin Immunol; 2016 Dec; 138(6):1730-1732. PubMed ID: 27567329
[No Abstract] [Full Text] [Related]
17. Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria.
Ertas R; Ozyurt K; Ozlu E; Ulas Y; Avci A; Atasoy M; Hawro T; Maurer M
J Allergy Clin Immunol; 2017 Dec; 140(6):1749-1751. PubMed ID: 28870460
[No Abstract] [Full Text] [Related]
18. Elevated IgE to tissue factor and thyroglobulin are abated by omalizumab in chronic spontaneous urticaria.
Cugno M; Asero R; Ferrucci S; Lorini M; Carbonelli V; Tedeschi A; Marzano AV
Allergy; 2018 Dec; 73(12):2408-2411. PubMed ID: 30076634
[No Abstract] [Full Text] [Related]
19. Real-life treatment of cholinergic urticaria with omalizumab.
Altrichter S; Chuamanochan M; Knoth H; Asady A; Ohanyan T; Metz M; Maurer M
J Allergy Clin Immunol; 2019 Feb; 143(2):788-791.e8. PubMed ID: 30312709
[No Abstract] [Full Text] [Related]
20. Omalizumab in the treatment of chronic urticaria.
Francés L; Leiva-Salinas M; Silvestre JF
Actas Dermosifiliogr; 2014; 105(1):45-52. PubMed ID: 23938072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
